Threshold Pharmaceuticals Director Unloads $3,532,632 in Stock (THLD)
Threshold Pharmaceuticals (NASDAQ:THLD) Director Wilfred Jaeger unloaded 723,900 shares of Threshold Pharmaceuticals stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $4.88, for a total value of $3,532,632.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Threshold Pharmaceuticals (NASDAQ:THLD) traded down 0.61% on Friday, hitting $4.85. 645,632 shares of the company’s stock traded hands. Threshold Pharmaceuticals has a 52-week low of $4.02 and a 52-week high of $6.11. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $4.79. The company has a market cap of $287.2 million and a P/E ratio of 40.33.
Threshold Pharmaceuticals (NASDAQ:THLD) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.16. The company had revenue of $3.20 million for the quarter, compared to the consensus estimate of $3.15 million. On average, analysts predict that Threshold Pharmaceuticals will post $-0.46 earnings per share for the current fiscal year.
Threshold Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors and the bone marrows of some hematologic malignancies (NASDAQ:THLD) as treatments for patients living with cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.